JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights.

Novo Nordisk’s obesity drug CagriSema’s test results showed an average weight loss of over 20%, but its stock slid in ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20 percent of their body weight, on average, a result that caused the Danish company’s ...

Although Novo will still make a mind-blowing amount of money from its existing obesity drugs in the coming years (its ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...

CagriSema-treated patients achieved superior weight loss compared with those who received cagrilintide 2.4mg, semaglutide 2.4mg or placebo. Topline data were announced from a phase 3 trial ...

In a phase 3 clinical trial investigating the usefulness of its anti-obesity drug candidate CagriSema, after being injected weekly for 68 weeks, patients lost 22.7% of their weight on average.

Novo Nordisk NVO has achieved the primary endpoint in a late-stage study evaluating its next-gen subcutaneous obesity treatment candidate, CagriSema. The results showed that treatment with the ...

On Monday, KeyBanc provided insights into the impact of Novo Nordisk (NYSE:NVO)'s Phase 3 results for its obesity treatment, CagriSema, on the GLP-1 market. The analysis suggests that the potential of ...

Investing.com -- Novo Nordisk (CSE:NOVOb) shares jumped over 9% on Monday, despite the company’s disappointing results for its experimental obesity treatment, CagriSema. This followed the release of ...